This clinical trial is focused on studying the treatment of septic shock, a serious condition that occurs when an infection leads to dangerously low blood pressure and organ failure. The study involves two treatments: one group will receive noradrenaline combined with a placebo, while the other group will receive noradrenaline combined with terlipressin. Noradrenaline is a medication that helps increase blood pressure by narrowing blood vessels, and terlipressin is similar to a hormone that helps control blood pressure and reduce bleeding.
The purpose of the study is to see if adding terlipressin to noradrenaline can help reduce organ failure and increase the number of days patients can spend outside of the intensive care unit (ICU) within 28 days. Participants will be randomly assigned to one of the two treatment groups, and neither the participants nor the researchers will know which treatment each participant is receiving. This is known as a “double-blind” study, which helps ensure the results are not biased.
Throughout the study, researchers will monitor the participants’ health, focusing on how well their organs are functioning and how many days they can spend without needing intensive care. The study will also look at other factors, such as the clearance of lactate (a substance that can build up in the blood during severe illness), the number of days without needing mechanical ventilation, and the overall survival rate. The study aims to provide valuable information on whether the combination of noradrenaline and terlipressin is more effective than noradrenaline alone in treating septic shock.
Spain 
